TVTX

SEC source: 0001209191-21-007031 · doc4.xml · nonDerivative · entry 1

Rosenberg Noah L. · CIK 0001579649 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,720

F1 · kind: On January 31, 2020, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 10,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. On January 31, 2021, a portion of the PRSUs vested upon the 12 month anniversary of the date of grant, following the Issuer's prior confirmation of the satisfaction of a performance criterion related to the full enrollment of the DUPLEX study.

SEC source: 0001209191-21-007028 · doc4.xml · nonDerivative · entry 1

ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,582

F1 · kind: On January 31, 2020, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 10,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. On January 31, 2021, a portion of the PRSUs vested upon the 12 month anniversary of the date of grant, following the Issuer's prior confirmation of the satisfaction of a performance criterion related to the full enrollment of the DUPLEX study.

SEC source: 0001209191-21-007026 · doc4.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,055

F1 · kind: On January 31, 2020, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 10,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. On January 31, 2021, a portion of the PRSUs vested upon the 12 month anniversary of the date of grant, following the Issuer's prior confirmation of the satisfaction of a performance criterion related to the full enrollment of the DUPLEX study.

SEC source: 0001209191-21-007025 · doc4.xml · nonDerivative · entry 1

Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,079

F1 · kind: On January 31, 2020, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 30,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. On January 31, 2021, a portion of the PRSUs vested upon the 12 month anniversary of the date of grant, following the Issuer's prior confirmation of the satisfaction of a performance criterion related to the full enrollment of the DUPLEX study.

SEC source: 0001209191-21-007024 · doc4.xml · nonDerivative · entry 1

Clague Laura · CIK 0001388773 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,473

F1 · kind: On January 31, 2020, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 10,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. On January 31, 2021, a portion of the PRSUs vested upon the 12 month anniversary of the date of grant, following the Issuer's prior confirmation of the satisfaction of a performance criterion related to the full enrollment of the DUPLEX study.

SEC source: 0001209191-21-005254 · doc4.xml · derivative · entry 2

ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,500

Underlying: Common Stock · 57,500 shares

Expires 2031-01-20

F3 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-005254 · doc4.xml · nonDerivative · entry 1

ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,582

F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan that are scheduled to vest over four years.

F2 · balance_after: Includes 496 shares of the Issuer's common stock acquired by the reporting person on November 30, 2020 pursuant to an employee stock purchase program.

SEC source: 0001209191-21-005253 · doc4.xml · derivative · entry 2

Rosenberg Noah L. · CIK 0001579649 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,500

Underlying: Common Stock · 57,500 shares

Expires 2031-01-20

F3 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-005253 · doc4.xml · nonDerivative · entry 1

Rosenberg Noah L. · CIK 0001579649 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,720

F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan that are scheduled to vest over four years.

F2 · balance_after: Includes 165 shares of the Issuer's common stock acquired by the reporting person on November 30, 2020 pursuant to an employee stock purchase program.

SEC source: 0001209191-21-005252 · doc4.xml · derivative · entry 2

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,500

Underlying: Common Stock · 57,500 shares

Expires 2031-01-20

F2 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-005252 · doc4.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,055

F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan that are scheduled to vest over four years.

SEC source: 0001209191-21-005251 · doc4.xml · derivative · entry 2

Heerma Peter · CIK 0001789617 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,500

Underlying: Common Stock · 57,500 shares

Expires 2031-01-20

F3 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-005251 · doc4.xml · nonDerivative · entry 1

Heerma Peter · CIK 0001789617 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,220

F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan that are scheduled to vest over four years.

F2 · balance_after: Includes 891 shares of the Issuer's common stock acquired by the reporting person on November 30, 2020 pursuant to an employee stock purchase program.

SEC source: 0001209191-21-005250 · doc4.xml · derivative · entry 2

Clague Laura · CIK 0001388773 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,500

Underlying: Common Stock · 57,500 shares

Expires 2031-01-20

F2 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-005250 · doc4.xml · nonDerivative · entry 1

Clague Laura · CIK 0001388773 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,473

F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan that are scheduled to vest over four years.

SEC source: 0001209191-21-005249 · doc4.xml · derivative · entry 2

Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 212,600

Underlying: Common Stock · 212,600 shares

Expires 2031-01-20

F2 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-005249 · doc4.xml · nonDerivative · entry 1

Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,079

F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan that are scheduled to vest over four years.

SEC source: 0001209191-21-005944 · doc4a.xml · derivative · entry 1

Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 212,660

Underlying: Common Stock · 212,660 shares

Expires 2031-01-20

F1 · kind: This amendment is being filed solely to correct an administrative error in the original Form 4, which reported the number of shares subject to the stock option as 212,600 instead of 212,660.

F2 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-002595 · doc4.xml · nonDerivative · entry 2

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,055

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-21-002592 · doc4.xml · nonDerivative · entry 2

Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,819

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-21-002595 · doc4.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,743

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-21-002592 · doc4.xml · nonDerivative · entry 1

Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,257

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-20-063929 · doc4.xml · nonDerivative · entry 1

ASELAGE STEVE · CIK 0001221599 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 196,667

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.99 to $26.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-20-061869 · doc4.xml · nonDerivative · entry 2

ASELAGE STEVE · CIK 0001221599 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 202,216

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.42 to $23.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-20-060591 · doc4.xml · nonDerivative · entry 3

Clague Laura · CIK 0001388773 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,473

F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

SEC source: 0001209191-20-060591 · doc4.xml · nonDerivative · entry 2

Clague Laura · CIK 0001388773 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,223

F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

SEC source: 0001209191-20-060591 · doc4.xml · nonDerivative · entry 1

Clague Laura · CIK 0001388773 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,973

F1 · kind: On May 17, 2017, the reporting person was granted performance restricted stock units (PRSUs) covering 15,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On November 23, 2020, a portion of the PRSUs vested upon the Issuer's confirmation of the satisfaction of a performance criterion.

SEC source: 0001209191-20-061869 · doc4.xml · nonDerivative · entry 1

ASELAGE STEVE · CIK 0001221599 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 210,107

SEC source: 0001209191-20-058943 · doc4.xml · nonDerivative · entry 1

ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,086

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.75 to $24.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-20-058945 · doc4.xml · nonDerivative · entry 1

Clague Laura · CIK 0001388773 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,473

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.68 to $24.485, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-20-058944 · doc4.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,431

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.74 to $24.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-20-058418 · doc4.xml · nonDerivative · entry 2

ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,586

F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.36 to $23.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-20-058419 · doc4.xml · nonDerivative · entry 2

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,931

F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.36 to $23.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-20-058417 · doc4.xml · nonDerivative · entry 2

Clague Laura · CIK 0001388773 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,973

F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.36 to $24.105, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-20-058418 · doc4.xml · nonDerivative · entry 1

ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,086

F1 · kind: On February 13, 2017, the reporting person was granted performance restricted stock units (PRSUs) covering 15,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On November 11, 2020, a portion of the PRSUs vested upon the Issuer's confirmation that the Issuer had completed a significant acquisition.

SEC source: 0001209191-20-058419 · doc4.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,431

F1 · kind: On January 4, 2017, the reporting person was granted performance restricted stock units (PRSUs) covering 15,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On November 11, 2020, a portion of the PRSUs vested upon the Issuer's confirmation that the Issuer had completed a significant acquisition.

SEC source: 0001209191-20-058417 · doc4.xml · nonDerivative · entry 1

Clague Laura · CIK 0001388773 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,473

F1 · kind: On May 19, 2016, the reporting person was granted performance restricted stock units (PRSUs) covering 15,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On November 11, 2020, the PRSUs vested upon the Issuer's confirmation that the Issuer had completed a significant acquisition.

SEC source: 0001209191-20-057381 · doc4.xml · nonDerivative · entry 2

ASELAGE STEVE · CIK 0001221599 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 213,107

F1 · kind: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

SEC source: 0001209191-20-057381 · doc4.xml · nonDerivative · entry 1

ASELAGE STEVE · CIK 0001221599 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 233,732

F1 · kind: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

SEC source: 0001209191-20-053925 · doc4.xml · nonDerivative · entry 2

Heerma Peter · CIK 0001789617 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,329

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-20-053925 · doc4.xml · nonDerivative · entry 1

Heerma Peter · CIK 0001789617 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,517

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

F2 · balance_after: Includes 2,705 shares of the Issuer's common stock acquired by the reporting person on May 31, 2020 pursuant to an employee stock purchase program.

SEC source: 0001209191-20-051736 · doc4.xml · nonDerivative · entry 1

ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,086

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

SEC source: 0001209191-20-051735 · doc4.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,431

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

SEC source: 0001209191-20-051734 · doc4.xml · nonDerivative · entry 1

Rosenberg Noah L. · CIK 0001579649 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,555

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

SEC source: 0001209191-20-051732 · doc4.xml · nonDerivative · entry 1

Clague Laura · CIK 0001388773 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,473

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

SEC source: 0001209191-20-051614 · doc4.xml · nonDerivative · entry 2

Rosenberg Noah L. · CIK 0001579649 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,305

F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

SEC source: 0001209191-20-051615 · doc4.xml · nonDerivative · entry 2

ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,586

F3 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

SEC source: 0001209191-20-051613 · doc4.xml · nonDerivative · entry 2

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,931

F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

SEC source: 0001209191-20-051612 · doc4.xml · nonDerivative · entry 2

Clague Laura · CIK 0001388773 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,973

F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

SEC source: 0001209191-20-051611 · doc4.xml · nonDerivative · entry 4

Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,695

F3 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.